Height and weight development following cyclical intravenous pamidronate in children and adolescents with chronic recurrent multifocal osteomyelitis (CRMO)

Methods 10 patients (5 M, 5 F) were enrolled, with mean (range) age 11.4 (4.5–16.3) years at IVP treatment. All patients received a 3-day infusion of IVP (0.5 mg/kg/day for the first dose; 1 mg/kg/day subsequently), followed by 1-day infusion monthly or 3-day infusion every 3 months until resolution of MRI documented bone inflammation. Weight and height were measured prior to first IVP, at 1year, and at final follow-up, and results were transformed into ageand gender-matched z-scores. Hotelling's test on the bivariate height and weight differences between 2 time points was performed.